The US Food and Drug Administration (FDA) has notified health professionals, their provider organisations, and caregivers for infants, that prescription oral viscous lidocaine 2% solution should not be used to treat infants and children with teething pain.
The FDA is requiring a Boxed Warning to be added to the prescribing information to highlight this information. Oral viscous lidocaine solution is not approved to treat teething pain, and use in infants and young children can cause serious harm, including death.
Topical pain relievers and medications that are rubbed on the gums are not necessary or even useful because they wash out of the baby’s mouth within minutes. When too much viscous lidocaine is given to infants and young children or they accidentally swallow too much, it can result in seizures, severe brain injury, and problems with the heart. Cases of overdose due to incorrect dosing or accidental ingestion have resulted in infants and children being hospitalised or dying.
In 2014, the FDA reviewed 22 case reports of serious adverse reactions, including deaths, in infants and young children aged 5 months to 3.5 years of age who were given oral viscous lidocaine 2% solution for the treatment of mouth pain, including teething and stomatitis, or who had accidental ingestions.
Healthcare professionals should not prescribe or recommend this product for teething pain. Parents and caregivers should follow the recommendations of the American Academy of Pediatric (AAP) for treating teething pain.
• Use a teething ring chilled in the refrigerator (not frozen).
• Gently rub or massage the child’s gums with your finger to relieve the symptoms.
The FDA is also encouraging parents and caregivers not to use topical medications for teething pain that are available over the counter (OTC) because some of them can be harmful. The FDA recommends following the AAP’s recommendations to help lessen teething pain.
SOURCE: US Food and Drug Administration